OBJECTIVE: To analyze the indications for and the efficacy of parenteral fosfomycin, especially against multidrug-resistant (MDR) and pan-resistant bacterial infections. PATIENTS AND METHODS: During a unique crisis in fosfomycin production, the supply of this antibiotic had to be carefully monitored in France over a 10-week period. One hundred and sixteen assessable patients were included in a prospective cohort study. RESULTS: The main indications for use were osteoarthritis, lung infection, urinary tract infection, and bacteraemia. The 2 bacteria most frequently involved were Pseudomonas aeruginosa and methicillin-resistant Staphylococcus. MDR bacteria were seen in 71.5% (83/116) of cases, especially MDR P. aeruginosa (n = 28). Critical situations were common, with 44.0% (51/116) of hospitalizations occurring in an intensive care unit and 22.4% (26/116) of patients with septic shock. The overall outcome was favourable in 76.8% of cases (76/99 assessable patients). CONCLUSION: This study provided a unique opportunity to describe the use of fosfomycin and assess its efficacy, especially against MDR bacterial infections, even in critical situations.
OBJECTIVE: To analyze the indications for and the efficacy of parenteral fosfomycin, especially against multidrug-resistant (MDR) and pan-resistant bacterial infections. PATIENTS AND METHODS: During a unique crisis in fosfomycin production, the supply of this antibiotic had to be carefully monitored in France over a 10-week period. One hundred and sixteen assessable patients were included in a prospective cohort study. RESULTS: The main indications for use were osteoarthritis, lung infection, urinary tract infection, and bacteraemia. The 2 bacteria most frequently involved were Pseudomonas aeruginosa and methicillin-resistant Staphylococcus. MDR bacteria were seen in 71.5% (83/116) of cases, especially MDR P. aeruginosa (n = 28). Critical situations were common, with 44.0% (51/116) of hospitalizations occurring in an intensive care unit and 22.4% (26/116) of patients with septic shock. The overall outcome was favourable in 76.8% of cases (76/99 assessable patients). CONCLUSION: This study provided a unique opportunity to describe the use of fosfomycin and assess its efficacy, especially against MDR bacterial infections, even in critical situations.
Authors: Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132
Authors: C Putensen; B Ellger; S G Sakka; A Weyland; K Schmidt; M Zoller; N Weiler; D Kindgen-Milles; U Jaschinski; J Weile; S Lindau; M Kieninger; A Faltlhauser; N Jung; P Teschendorf; M Adamzik; M Gründling; T Wahlers; H Gerlach; F-A Litty Journal: Infection Date: 2019-06-12 Impact factor: 3.553
Authors: Kelsey R Winchell; Paul W Egeler; Andrew J VanDuinen; Luke B Jackson; Mary E Karpen; Paul D Cook Journal: Biochemistry Date: 2016-08-11 Impact factor: 3.162
Authors: María Díez-Aguilar; María-Isabel Morosini; Rosa del Campo; María García-Castillo; Javier Zamora; Rafael Cantón Journal: Antimicrob Agents Chemother Date: 2013-08-12 Impact factor: 5.191